Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docosahexaenoic acid (DHA) gummy is a dietary supplement formulation of the omega-3 fatty acid docosahexaenoic acid, developed and marketed by Xiamen Bluebay Science & Technology. DHA is a primary structural component of the human brain, cerebral cortex, skin, and retina, and is essential for proper cognitive and visual development. The gummy formulation is designed to provide a palatable and convenient route of administration, particularly for children and developing individuals. DHA acts as an agonist of free fatty acid receptor 4 (FFAR4/GPR120) and peroxisome proliferator-activated receptor gamma (PPARG), modulating inflammatory pathways, enhancing synaptic plasticity, and supporting overall brain and eye health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docosahexaenoic acid gummy.